FDA Office of Prescription Drug Promotion (OPDP) · United States
FDA OPDP Patient Testimonial Marketing Standards
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
What is FDA OPDP Patient Testimonial Marketing Standards?
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information. Apply to prescription drug assets featuring patient stories, quotes, testimonials or before-and-after images. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability and any exceptions before making
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-11-06
What does this rule require?
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
How can marketing teams comply?
Apply to prescription drug assets featuring patient stories, quotes, testimonials or before-and-after images.
What is FDA OPDP Patient Testimonial Marketing Standards?
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
Under the Canadian Code of Advertising Standards, testimonials and endorsements must be genuine and based on real experience, material connections must be clearly disclosed, and Ad Standards' 2025 guidelines add disclosure of AI-generated content and virtual influencers.
Lawyer advertising in California may not present fabricated or synthetic testimonials, AI-generated depictions of lawyers, judges or clients as real, or AI chatbots as lawyers; guidance on generative AI (the State Bar Practical Guidance) applies the existing false-or-misleading-communication rules.
When a physician or other health professional endorses a drug, device or health service, any payment or other material connection to the advertiser must be clearly disclosed with the endorsement; the Sunshine Act's Open Payments reporting does not itself require ad disclosures.
Under the EU UCPD, traders must not present AI-generated or fictional people, reviews or product depictions as genuine consumer experiences or real results, and must explain how they verify reviews claimed to come from real buyers.
Lawyer advertising in the United States may not present fabricated or synthetic testimonials, AI-generated depictions of lawyers, judges or clients as real, or AI chatbots as lawyers; guidance on generative AI (Op. 512) applies the existing false-or-misleading-communication rules.
Request a free compliance scan of your homepage and book a time with Warrant.